瑞舒伐他汀与阿托伐他汀治疗急性心肌梗死的临床对比研究
|
摘要
目的:比较瑞舒伐他汀与阿托伐他汀治疗急性心肌梗死(AMI)的临床疗效。方法:选择2015年2月-2016年1月我院收治的AMI患者180例,按随机数字表法分为对照组和研究组,各90例。对照组给予口服阿托伐他汀(10 mg,qd)治疗,研究组给予口服瑞舒伐他汀(10 mg,qd)治疗。分别于治疗前后检测两组血清中血脂、炎症及心功能相关指标。结果 :与治疗前比较,两组治疗后血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、超敏C反应蛋白(hs-CRP)、白细胞介素(IL)-8、肿瘤坏死因子(TNF)-α、左室舒张末期内径(LVEDD)及左室质量指数水平明显下降(P<0.05),而高密度脂蛋白胆固醇(HDL-C)、左室射血分数(LVEF)及血管舒张功能(FMD)水平显著升高,且研究组治疗后以上血脂、炎症和心功能指标改善情况均显著优于对照组(P<0.05)。结论 :瑞舒伐他汀对于改善AMI患者的血脂、炎症因子和心脏功能均优于阿托伐他汀,值得临床推荐。
Objective:To compare the clinical effect of rosuvastatin and atorvastatin in treating acute myocardial infarction(AMI). Methods:180 AMI patients admitted in Dengfeng People's Hospital from February 2015 to January 2016 were randomly divided into control group and research group with 90 cases in each group. Patients in the control group were treated with oral atorvastatin(10 mg, qd), while patients in the research group were treated with rosuvastatin(10 mg, qd). Relevant indicators of serum lipid, inflammatory reactions and cardiac function were detected before and after treatment in both groups. Results:Compared with the results before treatment, the levels of total cholesterol(TC), triacylglycerol(TG), low density lipoprotein cholesterol(LDL-C), high sensitive C-reactive protein(hs-CRP), interleukin(IL)-8, tumor necrosis factor(TNF)-α, left ventricular end diastolic diameter(LVEDD) and left ventricular mass index(LVMI) after treatment in two groups declined obviously(P<0.05), while the levels of high density lipoprotein cholesterol(HDL-C), left ventricular ejection fraction(LVEF) and flow-mediated dilation(FMD) apparently raised(P<0.05). At the same time, the improvement of blood lipid, inflammatory cytokines, and cardiac function indexes after treatment in research group were significantly better than that in control group(P<0.05). Conclusion:Rosuvastatin showed superior effect on the clinical improvement in blood lipids, inflammatory factors and heart function in the patients with AMI, it is worth clinical recommendation,
Objective:To compare the clinical effect of rosuvastatin and atorvastatin in treating acute myocardial infarction(AMI). Methods:180 AMI patients admitted in Dengfeng People's Hospital from February 2015 to January 2016 were randomly divided into control group and research group with 90 cases in each group. Patients in the control group were treated with oral atorvastatin(10 mg, qd), while patients in the research group were treated with rosuvastatin(10 mg, qd). Relevant indicators of serum lipid, inflammatory reactions and cardiac function were detected before and after treatment in both groups. Results:Compared with the results before treatment, the levels of total cholesterol(TC), triacylglycerol(TG), low density lipoprotein cholesterol(LDL-C), high sensitive C-reactive protein(hs-CRP), interleukin(IL)-8, tumor necrosis factor(TNF)-α, left ventricular end diastolic diameter(LVEDD) and left ventricular mass index(LVMI) after treatment in two groups declined obviously(P<0.05), while the levels of high density lipoprotein cholesterol(HDL-C), left ventricular ejection fraction(LVEF) and flow-mediated dilation(FMD) apparently raised(P<0.05). At the same time, the improvement of blood lipid, inflammatory cytokines, and cardiac function indexes after treatment in research group were significantly better than that in control group(P<0.05). Conclusion:Rosuvastatin showed superior effect on the clinical improvement in blood lipids, inflammatory factors and heart function in the patients with AMI, it is worth clinical recommendation,
引文
[1]李连冲.瑞舒伐他汀、阿托伐他汀治疗早发冠心病急性心肌梗死患者的疗效观察[J].中西医结合心血管病杂志(电子版),2015,3(1):85-86.
[2]周云,渠乐,朱小莉.瑞舒伐他汀与阿托伐他汀治疗非ST段抬高型急性心肌梗死患者对炎症因子及左室重构的影响[J].海南医学院学报,2016,22(13):1390-1393.
[3]张胜.阿托伐他汀与瑞舒伐他汀治疗早发冠心病急性心肌梗死有效性及安全性的对比研究[J].实用心脑肺血管病杂志,2016,24(11):60-63.
[4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会,中国循环杂志编辑委员会.急性心肌梗死诊断和治疗指南(摘登)[J].新医学,2006,37(1):46.
[5]孙平,侯东彬,邱静,等.瑞舒伐他汀与阿托伐他汀对早发冠心病急性心肌梗死患者血管内皮功能和心脏功能的影响[J].基因组学与应用生物学,2016,35(8):1893-1898.
[6]赵文艺,胡中耀,任等.瑞舒伐他汀和阿托伐他汀在早发冠心病急性心肌梗死患者治疗中近期疗效[J].中国现代医生,2015,53(26):99-102.
[7]陆振涛.瑞舒伐他汀与阿托伐他汀对冠心病急性心肌梗死患者血管内皮功能的影响[J].医药论坛杂志,2015,36(11):40-42.
[8]吴萃荣,王湛.瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者PCI术后左室重构及近期预后影响的比较[J].实用医学杂志,2015,31(3):470-472.
[2]周云,渠乐,朱小莉.瑞舒伐他汀与阿托伐他汀治疗非ST段抬高型急性心肌梗死患者对炎症因子及左室重构的影响[J].海南医学院学报,2016,22(13):1390-1393.
[3]张胜.阿托伐他汀与瑞舒伐他汀治疗早发冠心病急性心肌梗死有效性及安全性的对比研究[J].实用心脑肺血管病杂志,2016,24(11):60-63.
[4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会,中国循环杂志编辑委员会.急性心肌梗死诊断和治疗指南(摘登)[J].新医学,2006,37(1):46.
[5]孙平,侯东彬,邱静,等.瑞舒伐他汀与阿托伐他汀对早发冠心病急性心肌梗死患者血管内皮功能和心脏功能的影响[J].基因组学与应用生物学,2016,35(8):1893-1898.
[6]赵文艺,胡中耀,任等.瑞舒伐他汀和阿托伐他汀在早发冠心病急性心肌梗死患者治疗中近期疗效[J].中国现代医生,2015,53(26):99-102.
[7]陆振涛.瑞舒伐他汀与阿托伐他汀对冠心病急性心肌梗死患者血管内皮功能的影响[J].医药论坛杂志,2015,36(11):40-42.
[8]吴萃荣,王湛.瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者PCI术后左室重构及近期预后影响的比较[J].实用医学杂志,2015,31(3):470-472.